MYMD Pharmaceuticals(MYMD) - 2020 Q4 - Annual Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the transition period from ____________ to ____________ Washington, D.C. 20549 Commission file number: 001-36268 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Akers Biosciences, Inc. (Exact name of registrant as specified in its charter) New Jersey 22-298378 ...